How many drugs treat Gilles de la Tourette's syndrome?

Drug Landscape tracks 2 marketed treatments for Gilles de la Tourette's syndrome (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Gilles de la Tourette's syndrome?

Most recent: Orap — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/gilles-de-la-tourette-s-syndrome.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Gilles de la Tourette's syndrome — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gilles de la Tourette's syndrome (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Gilles de la Tourette's syndrome, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Orap	PIMOZIDE	Teva	Typical Antipsychotic [EPC]	5-hydroxytryptamine receptor 7		1984-01-01
Haldol	haloperidol	Johnson & Johnson (Janssen)	Typical Antipsychotic [EPC]	3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A		1967-04-12

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-04-13 — Orap · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Johnson & Johnson (Janssen) · 1 drug in Gilles de la Tourette's syndrome
Teva · 1 drug in Gilles de la Tourette's syndrome

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Gilles de la Tourette's syndrome:

Cite this brief

Drug Landscape (2026). Gilles de la Tourette's syndrome — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/gilles-de-la-tourette-s-syndrome. Accessed 2026-06-10.

Gilles de la Tourette's syndrome full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing